<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40600020</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2392</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in endocrinology</Title><ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis on the efficacy and safety of Guanxin Shutong capsule in the treatment of angina pectoris of coronary heart disease.</ArticleTitle><Pagination><StartPage>1534752</StartPage><MedlinePgn>1534752</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1534752</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2025.1534752</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aims to summarize all single clinical studies of Guanxin Shutong (GXST) capsule combined with Western medicine in the treatment of coronary heart disease angina pectoris and to systematically evaluate its efficacy and safety.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Chinese and English databases were searched to collect the randomized controlled trials (RCTs) of GXST capsule combined with conventional Western medicine in the treatment of patients with angina pectoris of coronary heart disease and to extract the data. Cochrane Risk of Bias Tool was used to evaluate literature quality, and RevMan5.3 software was used to evaluate the outcome indicators, such as total effective rate of angina pectoris, frequency of angina pectoris, duration of angina pectoris, total effective rate of electrocardiogram (ECG), lipid level, inflammatory factor level, hemorheology, cardiac function, and adverse reactions, and to assess publication bias.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 27 RCTs with 3440 cases were identified. The results showed that the combined use of GXST capsule was more effective in terms of total effective rate of angina pectoris, frequency of angina pectoris, duration of angina pectoris, and total effective rate of ECG. In addition, the combined use of GXST capsule had more advantages in reducing total cholesterol, low-density lipoprotein cholesterol, interleukin-6, tumor necrosis factor-&#x3b1;, high-sensitivity C-reactive protein, and whole-blood viscosity and increasing left ventricular ejection fraction and high-density lipoprotein cholesterol. However, for triglyceride and interleukin-1, there were two different results before and after the sensitivity analysis, which were attributed to the quality of the included literature. In terms of plasma viscosity and adverse reactions, after excluding the literature with large heterogeneity, sensitivity analysis indicated that the combined use of GXST capsule was helpful to reduce plasma viscosity and adverse reactions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">GXST capsule combined with conventional Western medicine has better efficacy and safety in the treatment of angina pectoris of coronary heart disease compared with Western medicine alone. However, our study still has some limitations. Thus, more standardized RCTs are needed in future studies to verify the conclusions, and longer follow-up periods need to be designed to explore the long-term efficacy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Wang, Zhang, Zhang, Yin, Zhao, Mao and Wang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaqin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Muchen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chinese Medicine, Shenyang Anning Hospital, Shenyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Expert Clinic, Traditional Chinese Medicine Hall, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Wenhao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shujun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang,&#xa0;China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics, Shenyang Women and Infants Hospital, Shenyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Wenjun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuewei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang,&#xa0;China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Endocrinol (Lausanne)</MedlineTA><NlmUniqueID>101555782</NlmUniqueID><ISSNLinking>1664-2392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002214">Capsules</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000787" MajorTopicYN="Y">Angina Pectoris</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003327" MajorTopicYN="Y">Coronary Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002214" MajorTopicYN="N">Capsules</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GXST capsule</Keyword><Keyword MajorTopicYN="N">coronary heart disease</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword><Keyword MajorTopicYN="N">traditional Chinese medicine</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40600020</ArticleId><ArticleId IdType="pmc">PMC12208842</ArticleId><ArticleId IdType="doi">10.3389/fendo.2025.1534752</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Krievins DK, Zellans E, Latkovskis G, Kumsars I, Krievina AK, Jegere S, et al. Diagnosis and treatment of ischemia-producing coronary stenoses improves 5-year survival of patients undergoing major vascular surgery. J Vasc Surg. (2024) S0741-5214:00500&#x2013;7. doi:&#xa0; 10.1016/j.jvs.2024.02.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvs.2024.02.043</ArticleId><ArticleId IdType="pubmed">38518962</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Lamee RK. Angina pectoris 2023: With and without obstructive coronary artery disease: Epidemiology, diagnosis, prognosis, and treatment. Vasc Pharmacol. (2024) 155:107285. doi:&#xa0; 10.1016/j.vph.2024.107285</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2024.107285</ArticleId><ArticleId IdType="pubmed">38431201</ArticleId></ArticleIdList></Reference><Reference><Citation>Balla C, Pavasini R, Ferrari R. Treatment of angina: where are we? Cardiology. (2018) 140:52&#x2013;67. doi:&#xa0; 10.1159/000487936</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000487936</ArticleId><ArticleId IdType="pubmed">29874661</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry TD, Satran D, Jolicoeur EM. Treatment of refractory angina in patients not suitable for revascularization. Nat Rev Cardiol. (2014) 11:78&#x2013;95. doi:&#xa0; 10.1038/nrcardio.2013.200</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2013.200</ArticleId><ArticleId IdType="pubmed">24366073</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nzel T, Daiber A, Gori T. More answers to the still unresolved question of nitrate tolerance. Eur Heart J. (2013) 34:2666&#x2013;73. doi:&#xa0; 10.1093/eurheartj/eht249</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht249</ArticleId><ArticleId IdType="pubmed">23864131</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y, Gao G, Leung SW. How efficacious are traditional Chinese medicine injections in treating angina pectoris? A network meta-analysis of randomized controlled trials. J Ethnopharmacol. (2023) 303:115996. doi:&#xa0; 10.1016/j.jep.2022.115996</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2022.115996</ArticleId><ArticleId IdType="pubmed">36509258</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Xu H, Yang G, Qiu Y, Liu J, Chen K. Oral Chinese proprietary medicine for angina pectoris: an overview of systematic reviews/meta-analyses. Complement. Ther Med. (2014) 22:787&#x2013;800. doi:&#xa0; 10.1016/j.ctim.2014.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctim.2014.05.011</ArticleId><ArticleId IdType="pubmed">25146083</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui X, Han S, Li J, Li W, Wang ZF, Zhang Q, et al. Clinical comprehensive evaluation of Guanxin Shutong Capsules in treatment of coronary heart disease angina pectoris with heart blood stasis syndrome. China J Chin. Mater Med. (2022) 47:1469&#x2013;75. doi:&#xa0; 10.19540/j.cnki.cjcmm.20211118.501</Citation><ArticleIdList><ArticleId IdType="doi">10.19540/j.cnki.cjcmm.20211118.501</ArticleId><ArticleId IdType="pubmed">35347945</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S, Wang JM, Li YY, Li D, Xu L, Hou TJ. The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv. Rev. (2015) 86:2&#x2013;10. doi:&#xa0; 10.1016/j.addr.2015.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2015.01.009</ArticleId><ArticleId IdType="pubmed">25666163</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac. Surg. (2011) 39:91&#x2013;2. doi:&#xa0; 10.1016/j.jcms.2010.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcms.2010.11.001</ArticleId><ArticleId IdType="pubmed">21145753</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, G&#xf8;tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. (2009) 151:W65&#x2013;94. doi:&#xa0; 10.7326/0003-4819-151-4-200908180-00136</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-4-200908180-00136</ArticleId><ArticleId IdType="pubmed">19622512</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Geng P, Zhang TT, Lu Q, Gao P, Mei J. Aceso: PICO-guided evidence summarization on medical literature. IEEE J Biomed Health Inform. (2020) PP:(3). doi:&#xa0; 10.1109/JBHI.2020.2984704</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/JBHI.2020.2984704</ArticleId><ArticleId IdType="pubmed">32275627</ArticleId></ArticleIdList></Reference><Reference><Citation>
McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV. Chapter9: summarizing study characteristics and preparing for synthesis. In: Higgins JPT, Thomas j., Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022).
London: Cochrane;  (2022). Available at: www.training.cochrane.org/handbook (Accessed January 21, 2024).</Citation></Reference><Reference><Citation>Sterne JAC, Savovi&#xe9; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. (2019) 366:14898. doi:&#xa0; 10.1136/bmj.148983</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.148983</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhang L, Lv SZ, Wang XZ, Zhang J, Tian XX, et al. Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial. BMC Complement Altern. Med. (2019) 19:363. doi:&#xa0; 10.1186/s12906-019-2778-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12906-019-2778-z</ArticleId><ArticleId IdType="pmc">PMC6907120</ArticleId><ArticleId IdType="pubmed">31829173</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai RY. Treatment effects, safety and effective rates of guanxin shutong capsule in angina pectoris with hypertension. Liaoning J Tradit. Chin. Med. (2022) 49:127&#x2013;30. doi:&#xa0; 10.13192/j.issn.1000-1719.2022.06.035</Citation><ArticleIdList><ArticleId IdType="doi">10.13192/j.issn.1000-1719.2022.06.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao XY, Yue YY. Clinical effect of Guanxin Shutong capsule on angina pectoris of coronary heart disease. Guid. Chin. Med. (2013) 11:249&#x2013;50. doi:&#xa0; 10.15912/j.cnki.gocm.2013.26.030</Citation><ArticleIdList><ArticleId IdType="doi">10.15912/j.cnki.gocm.2013.26.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Chen YQ, Xiao Y, Liu D, Cao XH, Zhao HM. The influence of guanxin shutong capsule and trimetazidine dihydrochloride on the expressions of IL-6 and NT-proBNP in patients with unstable angina pectoris. Chin. J Integr Med Cardio-Cerebrovasc. Dis. (2016) 14:2484&#x2013;6. doi:&#xa0; 10.3969/j.issn.1672-1349.2016.21.005</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1672-1349.2016.21.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gou WH, Zhang D. Efficacy of guanxinshutong capsule combined with metoprolol in the treatment of unstable angina pectoris and its effects on hemorheology and inflammatory factors. Eval. Anal Drug-Use Hosp. China. (2020) 20:1075&#x2013;1077 + 1082. doi:&#xa0; 10.14009/j.issn.1672-2124.2020.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.14009/j.issn.1672-2124.2020.09.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo DQ, Li P. Clinical observation of Guanxinshutong capsule in the treatment of unstable angina pectoris. Chin. J Clin. (2013) 41:37&#x2013;8. doi:&#xa0; 10.3969/j.issn.1008-1089.2013.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1008-1089.2013.12.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji YY. Effect of Guanxinshutong capsule on stable angina pectoris of coronary heart disease. Cardiovasc Dis J Integr Tradit. Chin. West Med. (2017) 5:169 + 172. doi:&#xa0; 10.16282/j.cnki.cn11-9336/r.2017.01.127</Citation><ArticleIdList><ArticleId IdType="doi">10.16282/j.cnki.cn11-9336/r.2017.01.127</ArticleId></ArticleIdList></Reference><Reference><Citation>
Jia QF, Li XW. Clinical observation of Guanxinshutong capsule combined with fluvastatin in the treatment of angina pectoris of coronary heart disease. J Pract Tradit. Chin. Med. (2023) 39:1555&#x2013;7. Available at: https://www.cnki.com.cn/Article/CJFDTOTAL-ZYAO202308028.htm (Accessed December 21, 2023).</Citation></Reference><Reference><Citation>
Li XB, Li JX, Li ZH. Effect of Guanxinshutong capsule on myocardial insufficiency of coronary heart disease. Pract J Card Cereb Pneumal Vasc Dis. (2014) 22:131&#x2013;2. Available at: https://www.cnki.com.cn/Article/CJFDTOTAL-SYXL201409078.htm (Accessed December 21, 2023).</Citation></Reference><Reference><Citation>Liang B. Clinical observation of 43 cases of unstable angina pectoris treated with Guanxinshutong capsule. Yunnan J Tradit. Chin. Med Mater Med. (2015)36:23&#x2013;4. doi:&#xa0; 10.16254/j.cnki.53-1120/r.2015.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.16254/j.cnki.53-1120/r.2015.02.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YC. Effect of Guanxinshutong capsule on vascular endothelial cell function in patients with unstable angina pectoris. J New Chin. Med. (2016) 48:18&#x2013;20. doi:&#xa0; 10.13457/j.cnki.jncm.2016.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.13457/j.cnki.jncm.2016.05.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SS, Li J, Shi YX, Huang ZZ, Li ZG. Effect of Guanxinshutong capsule combined with metoprolol on angina pectoris and plasma homocysteine level in elderly patients with coronary heart disease. Mod J Integr Tradit. Chin. West Med. (2019) 28:1892&#x2013;5. doi:&#xa0; 10.3969/j.issn.1008-8849.2019.17.017</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1008-8849.2019.17.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo SF. The Clinical Efficacy of Coronary Heart Sultan Capsule combined with Western Medicine to Treat Coronary Heart Disease Stable Angina and its Effect on Blood Lipids and hs-CRP. Smart Healthc. (2021) 7:173&#x2013;5. doi:&#xa0; 10.19335/j.cnki.2096-1219.2021.08.056</Citation><ArticleIdList><ArticleId IdType="doi">10.19335/j.cnki.2096-1219.2021.08.056</ArticleId></ArticleIdList></Reference><Reference><Citation>
Miao LJ, Cheng GS. Effect of Guanxinshutong Capsule on electrocardiogram and myocardial enzyme in patients with unstable angina pectoris. Asia-Pac. Tradit. Med. (2017) 13:152&#x2013;4. Available at: https://www.cnki.com.cn/Article/CJFDTOTAL-YTCT201716065.htm (Accessed December 21, 2023).</Citation></Reference><Reference><Citation>Pan L, Li P, Ouyang Sk, Song H, Li JX. Effects of guanxinshutong capsule combined with nicorandil on cardiac function, hemorheology and inflammatory factors in patients with stable angina pectoris and heart blood stasis type. Prog Mod Biomed. (2022) 22:4125&#x2013;4129 + 4152. doi:&#xa0; 10.13241/j.cnki.pmb.2022.21.022</Citation><ArticleIdList><ArticleId IdType="doi">10.13241/j.cnki.pmb.2022.21.022</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ren SH, Zhang RJ, Ke SX, Liu JB, Shi YF, Guo Y, et al. Effects of Guanxinshutong Capsule on cardiac function and hemorheology in patients with coronary heart disease. J Pract Tradit. Chin. Med. (2017) 33:492&#x2013;3. Available at: https://www.cnki.com.cn/Article/CJFDTOTAL-ZYAO201705022.htm (Accessed December 21, 2023).</Citation></Reference><Reference><Citation>Shi H. Effect of guanxin shutong capsule(&#x51a0;&#x5fc3;&#x8212;&#x901a;&#x80f6;&#x56ca;) combined with metoprolol in treatment of stable angina pectoris of coronary heart disease and its influence on blood lipids and hs-CRP. Liaoning J Tradit. Chin. Med. (2022) 49:137&#x2013;40. doi:&#xa0; 10.13192/j.issn.1000-1719.2022.09.039</Citation><ArticleIdList><ArticleId IdType="doi">10.13192/j.issn.1000-1719.2022.09.039</ArticleId></ArticleIdList></Reference><Reference><Citation>
Shi J, Abudujili A. Clinical study of Guanxinshutong capsule in treating stable angina pectoris of coronary heart disease. Chin. J Integr Med Cardio-Cerebrovasc. Dis. (2018) 16:199&#x2013;201. Available at: https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY201802020.htm (Accessed December 21, 2023).</Citation></Reference><Reference><Citation>Song JH. Exploring the effect of Guanxin Shutong capsule combined with Western medicine in the treatment of coronary heart disease angina pectoris. Cardiovasc Dis J Integr Tradit. Chin. West Med. (2016) 4:39 + 41. doi:&#xa0; 10.16282/j.cnki.cn11-9336/r.2016.04.022</Citation><ArticleIdList><ArticleId IdType="doi">10.16282/j.cnki.cn11-9336/r.2016.04.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G. Clinical effect of Guanxinshutong capsule combined with isosorbide mononitrate tablet on patients with angina pectoris of coronary heart disease. Med Forum. (2021) 25:648&#x2013;50. doi:&#xa0; 10.19435/j.1672-1721.2021.05.028</Citation><ArticleIdList><ArticleId IdType="doi">10.19435/j.1672-1721.2021.05.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wu JS. Observe the clinical effect of Guanxin Shutong capsule treatment of Coronary heart disease with cariac blood stasis syndrome. Clin J Tradit. Chin. Med. (2015) 27:666&#x2013;8. doi:&#xa0; 10.16448/j.cjtcm.2015.0253</Citation><ArticleIdList><ArticleId IdType="doi">10.16448/j.cjtcm.2015.0253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu ZJ, Huang XX, Chen J. Clinical observation of Guanxinshutong capsule combined with Western medicine in the treatment of angina pectoris of coronary heart disease. J New Chin. Med. (2015) 47:43&#x2013;4. doi:&#xa0; 10.13457/j.cnki.jncm.2015.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.13457/j.cnki.jncm.2015.01.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang N, Zhang JJ. Clinical effect of Guanxin Shutong capsule combined with conventional western medicine on angina pectoris and its effect on inflammatory factors. Clin Res Prac. (2018) 3:4243. doi:&#xa0; 10.19347/j.cnki.2096-1413.201828018</Citation><ArticleIdList><ArticleId IdType="doi">10.19347/j.cnki.2096-1413.201828018</ArticleId></ArticleIdList></Reference><Reference><Citation>You ZC. Clinical efficacy and safety analysis of patients with coronary heart disease in patients with coronary heart disease in patients with coronary heart disease. Syst Med. (2021) 6:88&#x2013;90. doi:&#xa0; 10.19368/j.cnki.2096-1782.2021.19.088</Citation><ArticleIdList><ArticleId IdType="doi">10.19368/j.cnki.2096-1782.2021.19.088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao JS, Zhang YQ. Effects of Guanxin-shutong capsule on QT dispersion in patients with unstable angina pectoris. Hebei J Tradit. Chin. Med. (2015) 37:1698&#x2013;700. doi:&#xa0; 10.3969/j.issn.1002-2619.2015.11.035</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1002-2619.2015.11.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, Meng K, Ge CJ, Lv SZ. Curative effect of Guanxin Shutong Capsules on psychocardiacology in patients with chronic stable angina pectoris (syndrome of heart blood stasis). Chin. J Evid. Based Cardiovasc Med. (2015) 7:184&#x2013;7. doi:&#xa0; 10.3969/j.1674-4055.2015.02.10</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.1674-4055.2015.02.10</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu XJ, Liu J. Effect of Guanxinshutong capsule on patients with angina pectoris complicated with hypertension. Hebei Med J. (2017) 39:269&#x2013;71. doi:&#xa0; 10.3969/j.issn.1002-7386.2017.02.033</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1002-7386.2017.02.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Liu LF, Yao TM, Huo Y, Han YL. Cardioprotective effects of Guanxinshutong (GXST) against myocardial ischemia/reperfusion injury in rats. J Geriatr. Cardiol. (2012) 9:130&#x2013;6. doi:&#xa0; 10.3724/SP.J.1263.2011.11261</Citation><ArticleIdList><ArticleId IdType="doi">10.3724/SP.J.1263.2011.11261</ArticleId><ArticleId IdType="pmc">PMC3418901</ArticleId><ArticleId IdType="pubmed">22916058</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu YD, Sun YC, Jiang ZL, Zhang DD, Lin HC, Qu Y, et al. Guanxinshutong alleviates atherosclerosis by suppressing oxidative stress and proinflammation in apoE-/- mice. Evid. Based Complement Alternat. Med. (2020) 2020:1219371. doi:&#xa0; 10.1155/2020/1219371</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/1219371</ArticleId><ArticleId IdType="pmc">PMC7519182</ArticleId><ArticleId IdType="pubmed">33014098</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Yao TM, Huo Y, Han YL. The effects of Guanxinshutong on protection of left ventricular function after acute myocardial infarction in rats. Chin. J Intern Med. (2012) 51:225&#x2013;7. doi:&#xa0; 10.3760/cma.j.issn.0578-1426.2012.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0578-1426.2012.03.013</ArticleId><ArticleId IdType="pubmed">22781899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang LH, Wu CZ. Effeets of myocardial angiogenesis on Guanxin Shutong capsules in acute myocardial infaretion rats. J Changchun Univ Chin. Med. (2015) 31:451&#x2013;3. doi:&#xa0; 10.13463/j.cnki.cczyy.2015.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.13463/j.cnki.cczyy.2015.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu JQ, Zhou HF, Li C, He Y, Pan YM, Shou QY, et al. Guanxinshutong capsule ameliorates cardiac function and architecture following myocardial injury by modulating ventricular remodeling in rats. BioMed Pharmacother. (2020) 130:110527. doi:&#xa0; 10.1016/j.biopha.2020.110527</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110527</ArticleId><ArticleId IdType="pubmed">32688142</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi YT, Wang SD, Yuan LY, Liu XY, Wu W. Guanxin shutong capsule in the adjuvant treatment of unstable angina pectoris: A meta-analysis and trial sequential analysis. China Pharm. (2019) 30:956&#x2013;62. doi:&#xa0; 10.6039/j.issn.1001-0408.2019.07.20</Citation><ArticleIdList><ArticleId IdType="doi">10.6039/j.issn.1001-0408.2019.07.20</ArticleId><ArticleId IdType="pubmed">31602958</ArticleId></ArticleIdList></Reference><Reference><Citation>
Jia WX, Wei FX. Meta analysis of clinical effects and the safety of guanXin shuTong capsules in treating stable angina pectoris. West. J Tradit. Chin. Med. (2017) 30:67&#x2013;70. Available at: https://www.cnki.com.cn/Article/CJFDTOTAL-GSZY201708021.htm (Accessed December 21, 2023).</Citation></Reference><Reference><Citation>Sui JY, Xu H, Qin L, Xu GL. A meta-analysis of guanxin shutong capsule on patients with unstable angina. J Emerg Tradit. Chin. Med. (2016) 25:1863&#x2013;1865 + 1893. doi:&#xa0; 10.3969/j.issn.1004-745X.2016.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1004-745X.2016.10.009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>